Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2019-06-21 Director's Dealing
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于公司部分董事、监事和高级管理人员减持股份预披露公告
Director's Dealing Classification · 100% confidence The document is a public announcement regarding the planned reduction of shareholdings by certain company directors, supervisors, and senior management personnel. It details the shareholders involved, the number of shares to be reduced, the reasons for reduction, and the legal and regulatory compliance related to the share reduction. There is no financial data, earnings information, or report publication mentioned. The content fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades). The document length is 2525 characters, which is consistent with a detailed announcement but not a full financial report. Therefore, the appropriate classification is Director's Dealing (DIRS).
2019-06-21 Chinese
关于公司取得《药品GMP证书》的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (498 characters) about the company receiving a GMP certificate from a regulatory authority. It is a compliance or regulatory update rather than a financial report or detailed filing. It does not contain financial data, management changes, or voting results. It is not a report itself but an announcement of a certification. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement.
2019-06-13 Chinese
关于重组人生长激素注射液获得药品生产批件的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug production approval certificate from the National Medical Products Administration for a recombinant human growth hormone injection. It details the drug registration, approval, and market context. The document is short (1226 characters) and serves as an official announcement of regulatory approval rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed report data. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about product approval.
2019-06-13 Chinese
关于会计师事务所更名的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (510 characters) about the name change of the accounting firm serving the company. It explicitly states that this is not a change or reappointment of the accounting firm, and there is no financial data or report content included. The document is an official notification regarding the accounting firm's name change, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2019-06-12 Chinese
关于重组人生长激素注射液药品注册进度变更的提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the status change of a drug registration application for recombinant human growth hormone injection. It is a regulatory update about the progress of a pharmaceutical product registration, not a financial report or detailed filing. The document length is only 511 characters, and it serves as a notification to investors about the change in registration status. It does not contain financial data, management changes, voting results, or other report types. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-06-10 Chinese
关于全资子公司获得药物临床试验通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Anhui Anke Biological Engineering (Group) Co., Ltd. regarding its wholly-owned subsidiary obtaining a clinical trial notification from the National Medical Products Administration. It describes the approval for a new drug formulation clinical trial and provides details about the product and regulatory compliance. The document is short (733 characters) and serves as an official announcement of a regulatory milestone rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report types defined in the classification. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-05-13 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.